Join the Schizophrenia group to help and get support from people like you.
Schizophrenia News (Page 3)
Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia
Childhood BMI Linked to Increased Risk for Schizophrenia
MONDAY, Sept. 16, 2024 – Childhood body mass index (BMI) has a direct and enduring effect on the risk for schizophrenia later in life, according to a study published online Sept. 13 in Science...
Non-Substance-Related Mental Health Disorders Commonly Seen in Overdose Decedents
FRIDAY, Aug. 30, 2024 – More than one in five people who died of drug overdose in 2022 (21.9 percent) had a reported non-substance-related mental health disorder (MHD), according to research...
FDA Approves Erzofri (paliperidone palmitate) for the Treatment of Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., July 28, 2024 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that ...
Alterations in T Cell Subpopulations Linked to Brain Structure in Tardive Dyskinesia
THURSDAY, July 25, 2024 – Alterations in the proportion of T cell subpopulations are associated with brain structural abnormalities in patents with schizophrenia with tardive dyskinesia (TD),...
FDA Approves Risvan (risperidone) for the Treatment of Schizophrenia
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug Administration (FDA) has authorised the marketing of Risvan® (...
FDA Approves Uzedy (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
PARSIPPANY, N.J., TEL AVIV & PARIS, April 28, 2023 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced t...
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
April 28, 2023 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA)...
FDA Approves Rykindo (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Bipolar 1 Disorder
PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today ...
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for Caplyta (lumateperone) for Specific Patient Populations
Caplyta label now includes dosage recommendations for specific patient populations; those with moderate or severe hepatic impairment and patients who are concomitantly taking moderate or strong...
FDA Approves Igalmi (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
NEW HAVEN, Conn., April 06, 2022 (GLOBE NEWSWIRE) – BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop...
Intra-Cellular Therapies Announces U.S. FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults
Caplyta is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or...
FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder
DUBLIN, June 1, 2021 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment...
FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults
NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) – Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS)...
FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia
Miami, FL And Jersey City, NJ, October 15, 2019 -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration ...
Further information
Related condition support groups
Related drug support groups
Seroquel, Abilify, Latuda, quetiapine, Vraylar, olanzapine, risperidone, Zyprexa, Risperdal, view more... aripiprazole, Rexulti, Seroquel XR, Geodon, Invega, lurasidone, Invega Sustenna